Latest Ratios: P/E Ratio -3.8x · EV/EBITDA N/A · ROE -118.7%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $515M | $1.0B | $376M | $794M | $744M | $2.6B | — | — | — |
| Enterprise Value | $522M | $1.0B | $343M | $764M | $675M | $2.4B | — | — | — |
| P/E Ratio → | -3.83 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.91 | 6.41 | 1.50 | 2.76 | 1.49 | 3.54 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -118.7% | -118.7% | -99.2% | -72.0% | -43.9% | -231.6% | — | — | — |
| ROA | -53.2% | -53.2% | -50.0% | -40.8% | -27.6% | -38.3% | -49.8% | -58.2% | -38.6% |
| ROIC | -74.4% | -74.4% | -86.1% | -63.8% | -40.2% | -476.6% | — | — | — |
| ROCE | -48.1% | -48.1% | -57.0% | -48.4% | -31.3% | -41.3% | -29.4% | -65.9% | -25.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.49 | 0.49 | 0.38 | 0.36 | 0.22 | 0.15 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.04 | -0.13 | -0.10 | -0.14 | -0.20 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.89 | 1.89 | 3.54 | 3.31 | 3.99 | 5.62 | 12.22 | 7.47 | 18.26 |
| Quick Ratio | 1.89 | 1.89 | 3.54 | 3.31 | 3.99 | 5.62 | 12.22 | 7.47 | 18.26 |
| Cash Ratio | 1.76 | 1.76 | 3.36 | 3.18 | 3.80 | 5.55 | 12.03 | 7.19 | 17.16 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $253M | $231M | $195M | $188M | $166M | $188M | $187M | $187M |
Includes 30+ ratios · 8 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SANA stock.
Sana Biotechnology, Inc.'s current P/E ratio is -3.8x. This places it at the 50th percentile of its historical range.
Sana Biotechnology, Inc.'s return on equity (ROE) is -118.7%. The historical average is -113.1%.
Based on historical data, Sana Biotechnology, Inc. is trading at a P/E of -3.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Cash runway and dilution risk
Metrics are mathematically derived from official filings.
Book Value Premium Despite Pre-Revenue Status
Based on reported figures, SANA trades at 3.18 times book value with negative trailing earnings of -4.18 times P/E, a combination that signals investors are pricing pipeline optionality rather than current earnings power relative to clinical-stage peers.
A price-to-book of 3.18 for a company with negative returns on equity of -118.7% suggests the market is ascribing substantial value to clinical programs that are not yet reflected in book equity. Because goodwill of roughly $140.6 million forms a large share of book value, the multiple may be more sensitive to impairment risk than the headline figure implies. Investors should monitor whether the premium narrows as clinical milestones are reached or compresses if financing terms weaken.
Leverage Ratios Mask Thinning Equity Base
As reported in financial statements, SANA's debt-to-equity ratio of 0.30 in 2026Q3 appears moderate, but it rose from 0.63 in 2026Q1 only as equity eroded, indicating that the apparent deleveraging reflects a shrinking denominator rather than debt reduction.
The move in debt-to-equity over recent quarters appears driven more by equity loss from operating losses than by any change in the debt load, which may indicate a balance sheet becoming less resilient over time. Interest coverage is not meaningful given the absence of operating earnings, so debt service capacity depends entirely on access to external capital. This suggests refinancing or covenant risk warrants further investigation as cash reserves decline.
Current Ratio Flatters a Burn-Constrained Position
According to recent SEC filings, SANA's current ratio of 1.77 and quick ratio of 1.77 in 2026Q3 look comfortable, yet cash of $41.1 million against recurring operating outflows above $30 million per quarter implies only a few quarters of coverage.
With no inventory dependence, the quick and current ratios are identical and reflect short-term assets dominated by cash and investments that are being consumed quickly. The headline liquidity ratio therefore overstates the buffer relative to the burn rate. Under severe stress, a delayed financing could leave limited room before operations would need to be scaled back.
Working Capital Metrics Largely Unavailable
Based on reported figures, SANA's receivables, inventory, and payables cycle metrics are largely unavailable across the ten-quarter window apart from a single 71-day figure in 2026Q1, leaving cash conversion analysis limited.
Given the pre-revenue profile, asset turnover and days-sales metrics carry little analytical weight, and the data gap should not be read as evidence of operational inefficiency. The most informative efficiency signal is instead the decline in total assets and net PP&E, which may reflect a deliberate reduction in fixed-asset commitments. Investors should treat cash burn per program as the more relevant capital-efficiency measure.
Return Metrics Mislead on a Cash-Burning Platform
Based on reported figures, the most commonly misapplied ratio here is return on equity, where SANA's -118.7% reading reflects a shrinking equity base and operating losses rather than a durable measure of value destruction per dollar invested.
Return on equity is typically applied to profitable operating businesses, and for a clinical-stage biotech with minimal revenue it mainly reflects the size of the equity cushion relative to losses. A better lens is cash runway in quarters, combined with the probability-weighted value of each clinical program. This suggests the ratio should be read as a signal of financing dependence rather than a judgment on managerial returns.